title: Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.
abstract: During the 12-year period from 1993 to 2004, antimicrobial susceptibility profiles of 74,394 gram-negative bacillus isolates recovered from intensive care unit (ICU) patients in United States hospitals were determined by participating hospitals and collected in a central location. MICs for 12 different agents were determined using a standardized broth microdilution method. The 11 organisms most frequently isolated were Pseudomonas aeruginosa (22.2%), Escherichia coli (18.8%), Klebsiella pneumoniae (14.2%), Enterobacter cloacae (9.1%), Acinetobacter spp. (6.2%), Serratia marcescens (5.5%), Enterobacter aerogenes (4.4%), Stenotrophomonas maltophilia (4.3%), Proteus mirabilis (4.0%), Klebsiella oxytoca (2.7%), and Citrobacter freundii (2.0%). Specimen sources included the lower respiratory tract (52.1%), urine (17.3%), and blood (14.2%). Rates of resistance to many of the antibiotics tested remained stable during the 12-year study period. Carbapenems were the most active drugs tested against most of the bacterial species. E. coli and P. mirabilis remained susceptible to most of the drugs tested. Mean rates of resistance to 9 of the 12 drugs tested increased with Acinetobacter spp. Rates of resistance to ciprofloxacin increased over the study period for most species. Ceftazidime was the only agent to which a number of species (Acinetobacter spp., C. freundii, E. aerogenes, K. pneumoniae, P. aeruginosa, and S. marcescens) became more susceptible. The prevalence of multidrug resistance, defined as resistance to at least one extended-spectrum cephalosporin, one aminoglycoside, and ciprofloxacin, increased substantially among ICU isolates of Acinetobacter spp., P. aeruginosa, K. pneumoniae, and E. cloacae.
authors: Department of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242-1009, USA. shawn-lockhart@uiowa.edu
authors: Shawn R
authors: SR
authors: Lockhart
authors: Murray A
authors: MA
authors: Abramson
authors: Susan E
authors: SE
authors: Beekmann
authors: Gale
authors: G
authors: Gallagher
authors: Stefan
authors: S
authors: Riedel
authors: Daniel J
authors: DJ
authors: Diekema
authors: John P
authors: JP
authors: Quinn
authors: Gary V
authors: GV
authors: Doern
mesh_terms: D003428:Cross Infection / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D024841:Fluoroquinolones / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology*; D006801:Humans; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D013997:Time Factors; D014481:United States
chemical_list: D024841:Fluoroquinolones
references: Antimicrob Agents Chemother. 2003 May;47(5):1672-80
references: 12709339
references: Crit Care Med. 2003 Apr;31(4):1035-41
references: 12682469
references: Am J Infect Control. 2003 Dec;31(8):481-98
references: 14647111
references: Am J Med. 1991 Sep 16;91(3B):185S-191S
references: 1928163
references: Arch Intern Med. 1992 Mar;152(3):554-7
references: 1546918
references: Clin Infect Dis. 1996 Oct;23(4):779-84
references: 8909844
references: Antimicrob Agents Chemother. 1998 Jul;42(7):1762-70
references: 9661018
references: Chest. 1999 Feb;115(2):462-74
references: 10027448
references: Clin Infect Dis. 1999 Sep;29(3):595-607
references: 10530454
references: Infect Control Hosp Epidemiol. 2004 Oct;25(10):842-6
references: 15518026
references: Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):111-8
references: 15714332
references: Clin Infect Dis. 2005 Jun 15;40(12):1792-8
references: 15909268
references: Clin Infect Dis. 2005 Sep 15;41(6):848-54
references: 16107985
references: Surg Infect (Larchmt). 2002 Fall;3(3):259-67
references: 12542927
references: Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9
references: 16355321
references: Diagn Microbiol Infect Dis. 2005 Dec;53(4):265-71
references: 16360550
references: Antimicrob Agents Chemother. 2006 Feb;50(2):498-504
references: 16436702
references: Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S43-8
references: 16894514
references: Diagn Microbiol Infect Dis. 2007 Feb;57(2):207-15
references: 16949243
references: Chest. 2000 Jul;118(1):146-55
references: 10893372
references: J Antimicrob Chemother. 2000 Aug;46(2):223-8
references: 10933644
references: Clin Infect Dis. 2000 Sep;31(3):690-7
references: 11017817
references: Microb Drug Resist. 2000 Winter;6(4):297-303
references: 11272258
references: Clin Infect Dis. 2001 May 15;32 Suppl 2:S146-55
references: 11320454
references: Clin Infect Dis. 2001 Oct 15;33(8):1288-94
references: 11565067
references: Pharmacotherapy. 2002 Jan;22(1):81-7
references: 11794434
references: Emerg Infect Dis. 2002 May;8(5):473-8
references: 11996681
references: Emerg Infect Dis. 2002 Jul;8(7):697-701
references: 12095437
references: JAMA. 2003 Feb 19;289(7):885-8
references: 12588273
references: Infect Control Hosp Epidemiol. 2003 Aug;24(8):607-12
references: 12940583